TNSN04078A1 - Antibodies to cd40 - Google Patents

Antibodies to cd40

Info

Publication number
TNSN04078A1
TNSN04078A1 TNP2004000078A TNSN04078A TNSN04078A1 TN SN04078 A1 TNSN04078 A1 TN SN04078A1 TN P2004000078 A TNP2004000078 A TN P2004000078A TN SN04078 A TNSN04078 A TN SN04078A TN SN04078 A1 TNSN04078 A1 TN SN04078A1
Authority
TN
Tunisia
Prior art keywords
antibodies
relates
human
nucleic acid
acid molecules
Prior art date
Application number
TNP2004000078A
Other languages
English (en)
Inventor
Ronald P Gladue
José Corvalan
Vahe Bedian
Xiao Feng
Xiao-Chi Jia
Original Assignee
Abgenix Inc
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23370387&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN04078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenix Inc, Pfizer Prod Inc filed Critical Abgenix Inc
Publication of TNSN04078A1 publication Critical patent/TNSN04078A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE LES ANTICORPS ET LES PARTIES ANTIGENE - LIANTES DE TEL ANTICORPS QUI LIENT SPECIFIQUEMENT A CD40; CD40 DE PREFERENCE HUMAIN; ET QUI FONCTIONNENT COMME DES AGONISTES DE CD40. L' INVENTION SE RELIE EGALEMENT AUX ANTICORPS ANTI- CD40 HUMAINS ET AUX PARTIES ANTIGENE - LIANTES DE CELA. L' INVENTION SE RELIE EGALEMENT AUX ANTICORPS QUI SONT LES ANTICORPS OU LES PARTIES DE PROTEINES DE FUSION CHIMERIQUES; BISPECIFIQUES; DERIVATISES; A CHAINE SEULE. L INVENTION SE RELIE EGALEMENT AUX IMMUNOGLOBULINES A CHAINE LOURDE ET LEGERE ISOLEE DERIVEE DES ANTICORPS ANTI -CD40 HUMAINS ET DES MOLECULES D'ACIDE NUCLEIQUE CODANT ET DE TELLES IMMINOGLOBULINES. LA PRESENTE INVENTION SE RELIE EGALEMENT AUX METHODES DE LA FABRICATION DES ANTICORPS ANTI- CD40 HUMAINS; COMPOSITIONS COMPORTANT CES ANTICORPS ET DES METHODES D' EMPLOYER LES ANTICORPS ET LES COMPOSITIONS POUR LE DIAGNOSTIC ET LE TRAITEMENT. L INVENTION FOURNIT EGALEMENT DES METHODES DE THERAPIE DE GENE EN UTILISANT DES MOLECULES D ACIDE NUCLEIQUE CODANT LES MOLECULES LOURDES ET/ OU LEGERES D' IMMUNOGLOBULINE QUI COMPORTENT LES ANTICORPS ANTI- CD40 HUMAINS. L' INVENTION SE RELIE EGALEMENT AUX ANIMAUX DE TRANSFEREMENT GENIQUE (TRANSGENIQUE) COMPORTANT DES MOLECULES D 'ACIDE NUCLEIQUE DE LA PRESENTE INVENTION .
TNP2004000078A 2001-11-09 2004-05-05 Antibodies to cd40 TNSN04078A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34898001P 2001-11-09 2001-11-09
PCT/US2002/036107 WO2003040170A2 (fr) 2001-11-09 2002-11-08 Anticorps anti-cd40

Publications (1)

Publication Number Publication Date
TNSN04078A1 true TNSN04078A1 (fr) 2006-06-01

Family

ID=23370387

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000078A TNSN04078A1 (fr) 2001-11-09 2004-05-05 Antibodies to cd40

Country Status (47)

Country Link
US (9) US7288251B2 (fr)
EP (2) EP1476185B1 (fr)
JP (3) JP4616555B2 (fr)
KR (1) KR100830086B1 (fr)
CN (2) CN1582165B (fr)
AP (1) AP1918A (fr)
AR (1) AR039067A1 (fr)
AU (1) AU2002356926B2 (fr)
BR (1) BRPI0214137B8 (fr)
CA (1) CA2466128C (fr)
CL (1) CL2009001779A1 (fr)
CR (2) CR7343A (fr)
CU (1) CU23745A3 (fr)
CY (1) CY1115675T1 (fr)
DK (1) DK1476185T3 (fr)
DO (1) DOP2002000507A (fr)
EA (1) EA011449B1 (fr)
EC (1) ECSP045093A (fr)
EG (1) EG25801A (fr)
ES (1) ES2432968T3 (fr)
GE (1) GEP20074222B (fr)
GT (1) GT200200228A (fr)
HK (1) HK1069122A1 (fr)
HN (1) HN2002000318A (fr)
HR (1) HRP20040525B1 (fr)
HU (1) HU229829B1 (fr)
IL (2) IL161823A0 (fr)
IS (1) IS2940B (fr)
MA (1) MA27139A1 (fr)
ME (1) ME00503B (fr)
MX (1) MXPA04004467A (fr)
MY (1) MY137641A (fr)
NI (1) NI200200128A (fr)
NO (1) NO334339B1 (fr)
NZ (1) NZ533180A (fr)
OA (1) OA12725A (fr)
PA (1) PA8557701A1 (fr)
PE (1) PE20030846A1 (fr)
PL (2) PL214634B1 (fr)
PT (1) PT1476185E (fr)
RS (1) RS52484B (fr)
SI (1) SI1476185T1 (fr)
TN (1) TNSN04078A1 (fr)
TW (2) TWI338579B (fr)
UY (1) UY27537A1 (fr)
WO (1) WO2003040170A2 (fr)
ZA (1) ZA200404207B (fr)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) * 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US20050255106A1 (en) * 1999-05-22 2005-11-17 Linda Diehl Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2422204A1 (fr) 2000-09-07 2002-03-14 John R. Schreiber Anticorps humains diriges contre le lps de pseudomonas aeruginosa derives de souris transgeniques
EP2011802A3 (fr) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1480598A4 (fr) 2001-11-21 2006-03-22 Celltech R & D Inc Manipulation de taux de cytokine au moyen de produits de gene cd83
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
ES2381265T3 (es) * 2002-06-07 2012-05-24 Zymogenetics, Inc. Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005037235A2 (fr) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Inhibiteurs du recepteur 1 du facteur de croissance du fibroblaste et methodes therapeutiques associees
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PT1682180E (pt) * 2003-11-04 2010-02-10 Novartis Vaccines & Diagnostic Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização
CA2548015A1 (fr) 2003-12-05 2005-06-23 John R. Schreiber Anticorps humains diriges contre <i>pseudomonas-aeruginosa</i>, derives d'une xenosouris transgenique<sb> </sb>
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
NZ548325A (en) 2003-12-25 2009-07-31 Kirin Pharma Kk Mutants of anti-CD40 antibody
NL1027975C2 (nl) 2004-01-09 2005-12-23 Pfizer Antilichamen tegen MAdCAM.
CA2560742A1 (fr) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Agents de couplage recepteurs et leurs applications therapeutiques
ES2427147T3 (es) * 2004-06-30 2013-10-29 Mayo Foundation For Medical Education And Research Anticuerpo sHlgM12 útil para tratar esclerosis múltiple
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
DK1836225T3 (da) 2005-01-06 2012-02-27 Innate Pharma Sas Kir-bindingagenser og fremgangsmåde til anvendelse deraf
JP4986633B2 (ja) 2005-01-12 2012-07-25 協和発酵キリン株式会社 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
US7829673B2 (en) * 2005-03-23 2010-11-09 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2444419A1 (fr) 2005-04-26 2012-04-25 Pfizer Inc. Anticorps de la P-Cadherine
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
EP1894012A2 (fr) 2005-05-18 2008-03-05 Novartis AG Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
CA2616005C (fr) 2005-07-18 2015-09-22 Seattle Genetics, Inc. Conjugues lieur a base de beta-glucuronide-medicament
PE20080035A1 (es) 2005-09-07 2008-01-30 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
WO2007103048A2 (fr) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Conjugués de protéine agoniste de tlr (flagelline)/agoniste de cd40/ antigène et d'adn et leur utilisation pour induire un renforcement synergique de l'immunité
CN101479375B (zh) 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
AU2007251282A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP1854810A1 (fr) * 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
WO2007131575A1 (fr) * 2006-05-12 2007-11-22 Fondazione Centro San Raffaele Del Monte Tabor Cellules dendritiques tolérogènes, procédé pour leur production et leurs utilisations
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2103628A4 (fr) * 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
MX2009009080A (es) * 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
WO2008150494A1 (fr) 2007-05-30 2008-12-11 Xencor, Inc. Procédés et compositions permettant l'inhibition de cellules d'expression du cd32b
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
ES2526887T3 (es) 2007-12-14 2015-01-16 Bristol-Myers Squibb Company Método para producir moléculas de unión al receptor OX40 humano
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2010024676A1 (fr) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Administration d’un agoniste de cd40 à un ganglion lymphatique drainant une tumeur d’un sujet
EP2198878A1 (fr) 2008-12-18 2010-06-23 University Of Miami Antagonistes de bombésine en polypeptide
AU2016244220B2 (en) * 2008-12-23 2018-05-17 Amgen Inc. Human CGRP receptor binding proteins
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
JP2012519711A (ja) * 2009-03-06 2012-08-30 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
US9562104B2 (en) 2009-03-10 2017-02-07 Baylor Research Institute Anti-CD40 antibodies
EP3138854B1 (fr) 2009-03-10 2022-01-26 Baylor Research Institute Anticorps contre cd40
WO2010121231A1 (fr) 2009-04-18 2010-10-21 Genentech, Inc. Méthodes d'évaluation de la réactivité du lymphome b à un traitement utilisant un anticorps anti-cd40
HUE028537T2 (en) * 2009-04-20 2016-12-28 Kyowa Hakko Kirin Co Ltd Built-in amino acid mutation IgG2 antibody
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
WO2011083391A2 (fr) 2010-01-05 2011-07-14 Pfizer Inc. Biomarqueurs pour une thérapie du cancer par un anti-igf-1r
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
FR2959994B1 (fr) * 2010-05-12 2012-08-24 Lfb Biotechnologies Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
EP2614082B1 (fr) 2010-09-09 2018-10-03 Pfizer Inc Molécules de liaison 4-1bb
WO2012041635A1 (fr) * 2010-09-29 2012-04-05 Universite De Liege Association d'un anticorps monoclonal anti-cd40 agoniste ou d'un ligand du cd40 et d'une bactérie inactivée ou atténuée servant à traiter et/ou à prévenir la mastite
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP3974453A3 (fr) * 2010-11-16 2022-08-03 Amgen Inc. Agents et procédés pour traiter les maladies en corrélation avec l'expression bcma
CA2821117C (fr) * 2011-01-10 2019-02-12 Ct Atlantic Ltd. Polytherapie comprenant des anticorps se liant aux antigenes associes aux tumeurs
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
CA2852056C (fr) * 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anticorps anti-cd40 et leurs utilisations
WO2012145183A2 (fr) 2011-04-19 2012-10-26 Pfizer Inc. Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
RS57087B1 (sr) 2011-04-21 2018-06-29 Bristol Myers Squibb Co Polipeptidi antitela koji antagonizuju cd40
CN103702682A (zh) * 2011-04-21 2014-04-02 科罗拉多州立大学董事会法人团体 治疗视神经脊髓炎的组合物和方法
MX339239B (es) * 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
EP2710042A2 (fr) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA118332C2 (uk) 2011-09-22 2019-01-10 Емджен Інк. Білок, що зв'язує антиген cd27l
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013091661A2 (fr) * 2011-12-23 2013-06-27 Aarhus Universitet Etiquette d'affinité protéique résistante à la protéolyse
LT2809681T (lt) 2012-01-31 2019-02-11 Regeneron Pharmaceuticals, Inc. Antikūnai prieš asic1 ir jų panaudojimas
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2837387B1 (fr) * 2012-03-08 2020-07-29 Japan Science and Technology Agency Agent anticancéreux
KR20200075023A (ko) 2012-05-04 2020-06-25 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CA2877286C (fr) 2012-06-18 2023-05-16 Yale University Compositions et procedes pour faire diminuer une reponse immunitaire
AU2013337903B2 (en) * 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6539585B2 (ja) 2013-02-01 2019-07-03 デンドロサイト バイオテック ピーティーワイ リミテッド 抗ｃｄ８３抗体及びその使用
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
NZ712903A (en) 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
KR102094022B1 (ko) 2013-04-29 2020-03-30 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014202552A1 (fr) 2013-06-17 2014-12-24 Koninklijke Philips N.V. Support de sujet pour imagerie à résonance magnétique
GB201311487D0 (en) * 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
DK3444271T3 (da) 2013-08-08 2022-01-10 Cytune Pharma Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
EP3712166A1 (fr) 2013-09-05 2020-09-23 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
JP6345787B2 (ja) * 2013-12-20 2018-06-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ａｎｇ２抗体とｃｄ４０アゴニストとの併用療法
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
EP3113796A1 (fr) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
IL248257B1 (en) * 2014-04-30 2024-04-01 Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft Human antibodies against CD269(BCMA)
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
EA201790339A1 (ru) 2014-08-12 2017-06-30 Аллигатор Байосайенс Аб Комбинированные препараты с антителами к cd40
CA2949739A1 (fr) * 2014-08-14 2016-02-18 F. Hoffmann-La Roche Ag Polytherapie d'anticorps activant le cd-40 humain et d'anticorps anti-pd-l1 humain
EP3070102A1 (fr) 2015-03-18 2016-09-21 F. Hoffmann-La Roche AG Thérapie de combinaison a l'aide d'anticorps d'activation du cd40 humain et d'anticorps contre le récepteur humain pd-l1
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
EP3209695A4 (fr) 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Protéines de liaison cd83 et leurs utilisations
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR112017008880A2 (pt) 2014-10-29 2018-07-10 Teva Pharmaceuticals Australia Pty Ltd variantes de interferon a2b
SG11201702598XA (en) * 2014-10-29 2017-05-30 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
JP6931229B2 (ja) 2015-04-30 2021-09-01 サイオクサス セラピューティクス リミテッド Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AU2016285920A1 (en) * 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
PE20180315A1 (es) * 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
WO2017009843A2 (fr) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions, articles de fabrication et procédés pour traiter le cancer
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
US10544229B2 (en) 2015-09-30 2020-01-28 Janssen Biotech, Inc. Agonistic antibodies specifically binding CD40 and methods of use
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
CN114835797A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
CA3007311A1 (fr) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition de conjugues d'agonistes-constructions d'anticorps et leurs procedes d'utilisation
SG11201805137XA (en) 2015-12-17 2018-07-30 Psioxus Therapeutics Ltd Virus encoding an anti-tcr-complex antibody or fragment
MX2018010672A (es) 2016-03-04 2019-05-27 Univ Rockefeller Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
EP3426271A4 (fr) 2016-03-10 2019-10-16 Cold Genesys, Inc. Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
PE20190970A1 (es) 2016-05-27 2019-07-09 Abbvie Biotherapeutics Inc Anticuerpos anti-cd40 y sus usos
EP3464367B1 (fr) 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Protéines de liaison bispécifiques se liant à une protéine immunomodulatrice et à un antigène tumoral
JP7148504B2 (ja) 2016-06-08 2022-10-05 ゼンコー，インコーポレイティド ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
CN115304669A (zh) * 2016-06-08 2022-11-08 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
US20180044430A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them
WO2018031258A1 (fr) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018088850A2 (fr) 2016-11-11 2018-05-17 다이노나(주) Anticorps se liant spécifiquement à cd40 et utilisations associée
CA3047059A1 (fr) 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Nouveaux agonistes de tnfr et leurs utilisations
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
CA3049842A1 (fr) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Compositions de produit de recombinaison-peptide et leurs methodes d'utilisation
AU2018218345A1 (en) 2017-02-10 2019-08-29 Genmab B.V. Polypeptide variants and uses thereof
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
JP2020511959A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー ヒト化抗ｃｄ４０抗体
EP3604384B1 (fr) 2017-03-30 2021-09-08 NOF Corporation Dérivé de polymère hydrophile comportant un coupleur acétal auto-immolable et composite l'utilisant
US11419946B2 (en) 2017-03-30 2022-08-23 Nof Corporation Heterobifunctional monodispersed polyethylene glycol and conjugate using same
MA49039A (fr) * 2017-04-04 2020-02-12 Hoffmann La Roche Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
IL270989B2 (en) * 2017-06-01 2024-02-01 Akamis Bio Ltd Oncolytic virus and method
CA3064298A1 (fr) * 2017-06-01 2018-12-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Anticorps anti-cd40, fragment de liaison a l'antigene de celui-ci et utilisation medicale associee
EP3418302A1 (fr) 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Voies d'administration d'agonistes immunitaires
TW201902462A (zh) 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 用於免疫促效劑之新穎投與途徑
US20190169291A1 (en) 2017-07-14 2019-06-06 Pfizer Inc. Antibodies to MAdCAM
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
KR20200063139A (ko) 2017-09-19 2020-06-04 엠에이비 디스커버리 게엠베하 효능작용 cd40 항체
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN111344307A (zh) 2017-11-08 2020-06-26 协和麒麟株式会社 与CD40和EpCAM结合的双特异性抗体
WO2019133747A1 (fr) 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anticorps anti-cd40 et leurs utilisations
CN109971723B (zh) * 2017-12-28 2023-07-07 上海细胞治疗研究院 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
CN109971717B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019148444A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
JP7204078B2 (ja) 2018-03-13 2023-01-16 日油株式会社 主鎖および側鎖に単分散ポリエチレングリコールを有するヘテロ二官能性化合物
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
JP2021519790A (ja) 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
CA3097007A1 (fr) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anticorps anti-cd40 et leurs utilisations
WO2019217833A1 (fr) * 2018-05-10 2019-11-14 Abvision, Inc. Anticorps monoclonaux qui activent cd40 et leurs utilisations
WO2019232533A1 (fr) * 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Polythérapies à base d'inhibiteurs de hsp90 pour améliorer l'immunogénicité tumorale et leurs procédés d'utilisation
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
JP2021529556A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍アンタゴニスト
CN112912395A (zh) 2018-08-20 2021-06-04 辉瑞公司 抗gdf15抗体、组合物和使用方法
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
AU2019389354A1 (en) 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof
CN113677365A (zh) * 2019-01-22 2021-11-19 瑞伟生物科技公司(美国) 新型抗cd40抗体
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
JP2022527506A (ja) 2019-03-27 2022-06-02 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｃｄ４０活性化特性を有する組換えタンパク質
TW202103733A (zh) 2019-04-10 2021-02-01 南開大學 抗cd40抗體及其用途
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
US20220220216A1 (en) 2019-05-15 2022-07-14 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and gpc3
CN113891728A (zh) 2019-05-15 2022-01-04 协和麒麟株式会社 与cd40和fap结合的双特异性抗体
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
WO2021048135A1 (fr) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Combinaisons pharmaceutiques comprenant un furazanobenzimidazole et un agoniste de cd40 pour une utilisation dans le traitement de maladies néoplasiques
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
WO2021060439A1 (fr) 2019-09-26 2021-04-01 日油株式会社 Polyéthylène glycol monodispersé hétérobifonctionnel ayant un lieur peptidique
BR112022010680A2 (pt) * 2019-12-03 2022-08-16 Evotec Int Gmbh Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas
EP4076434A1 (fr) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
US20210214454A1 (en) * 2020-01-10 2021-07-15 Symphogen A/S Anti-cd40 antibodies and compositions
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multi-target antibodies for use in the treatment of diseases
WO2021215462A1 (fr) 2020-04-23 2021-10-28 ブライトパス・バイオ株式会社 Vaccin peptidique amélioré
AU2021271129A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Multispecific proteins
CA3178478A1 (fr) 2020-05-14 2021-11-18 Valerie Perrine Calabro Proteines de liaison a cd40 recombinantes et leur utilisation
EP4157343A2 (fr) 2020-05-26 2023-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides du coronavirus 2 associé au syndrome respiratoire aigu sévère (sars-cov-2) et leurs utilisations à des fins vaccinales
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4162257A1 (fr) 2020-06-04 2023-04-12 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
JP2023554587A (ja) 2020-11-12 2023-12-28 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｓａｒｓ－ｃｏｖ－２ スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用
US20240131138A1 (en) 2020-12-23 2024-04-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
WO2022147480A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique
WO2022150624A1 (fr) * 2021-01-08 2022-07-14 Bristol-Myers Squibb Company Anticorps et peptides de liaison à l'antigène pour des inhibiteurs du facteur xia et leurs utilisations
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
JP2024504195A (ja) 2021-01-29 2024-01-30 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） クラミジア・トラコマチス抗原性ポリペプチドおよびワクチン目的のためのその使用
WO2022165260A1 (fr) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Procédés de fabrication de lymphocytes infiltrant les tumeurs modifiés et leur utilisation dans la thérapie cellulaire adoptive
MX2023010512A (es) 2021-03-09 2023-12-08 Genmab As Agentes de union multiespecificos contra cd40 y cd137 en terapia.
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022261021A1 (fr) 2021-06-07 2022-12-15 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
AU2022301422A1 (en) * 2021-06-28 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd40 antibody, antigen-binding fragment and medical use thereof
EP4363059A1 (fr) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations
EP4370552A1 (fr) 2021-07-13 2024-05-22 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
EP4402174A1 (fr) * 2021-09-17 2024-07-24 Novartis AG Méthodes de prévention du rejet de greffe dans une xénogreffe
CN118139886A (zh) * 2021-10-01 2024-06-04 Mab发现股份有限公司 作为免疫刺激剂的激动性cd40抗体
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
WO2023147488A1 (fr) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine
WO2023172890A2 (fr) * 2022-03-07 2023-09-14 Agenus Inc. Anticorps anti-ilt2 et leurs utilisations
WO2023193239A1 (fr) 2022-04-08 2023-10-12 Peter Peizhi Luo Anticorps anti-cd28 et leurs procédés d'utilisation
WO2023198851A1 (fr) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Procédés de commande de la destruction de cellules tumorales par la lumière
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2024054992A1 (fr) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Procédés de séparation d'agent chélateur
WO2024059899A1 (fr) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Polypeptides bispécifiques et leurs utilisations
WO2024076969A1 (fr) * 2022-10-04 2024-04-11 Memorial Sloan-Kettering Cancer Center Anticorps anti-cd40 et leurs utilisations
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024074571A1 (fr) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Vaccin ciblant dc dirigé contre une infection par le virus nipah
WO2024118836A1 (fr) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs à étape rep raccourcie
WO2024115725A1 (fr) 2022-12-01 2024-06-06 BioNTech SE Anticorps multispécifique contre cd40 et cd137 en polythérapie avec un anticorps anti-pd1 et une chimiothérapie
CN115969997B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 一种靶向cldn18.2的抗体药物偶联物及其应用
CN116375870B (zh) * 2022-12-30 2023-09-15 优睿赛思(武汉)生物科技有限公司 抗人cd40蛋白的人源化抗体、制备方法及其应用
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59427A (en) * 1866-11-06 Improvement in fences
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US439216A (en) * 1890-10-28 Maker
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (fr) 1985-04-01 1986-10-09 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (fr) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546091B1 (fr) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Recombinaison homologue dans des cellules de mammiferes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
US5416367A (en) * 1991-03-06 1995-05-16 Quicklogic Corporation Programmable application specific integrated circuit and logic cell therefor
CA2108147C (fr) 1991-04-10 2009-01-06 Angray Kang Banques de recepteurs heterodimeriques construites a l'aide de phagemides
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH05242071A (ja) * 1991-11-20 1993-09-21 Mitsubishi Electric Corp 対象システムを制御または決定・推定する方法、およびその装置
EP0625200B1 (fr) 1992-02-06 2005-05-11 Chiron Corporation Proteine de liaison biosynthetique pour marqueur de cancer
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
NZ273504A (en) 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5612126A (en) * 1994-01-19 1997-03-18 Burlington Industries, Inc. Stiff fabric and method of forming the stiff fabric
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH0812700A (ja) 1994-07-01 1996-01-16 Sumitomo Electric Ind Ltd マウスｃｄ４０に対するモノクローナル抗体
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6132693A (en) * 1995-04-11 2000-10-17 Robert Bosch Gmbh Process and device for reducing pollutants, especially nitrogen oxides in combustion exhaust gases
CA2218503C (fr) 1995-04-20 2001-07-24 Pfizer Inc. Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
WO1996033266A1 (fr) 1995-04-21 1996-10-24 Cell Genesys, Inc. Creation d'importantes deletions d'adn genomique
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5780215A (en) * 1995-07-26 1998-07-14 Konica Corporation Silver halide color photographic light-sensitive material
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
CN1225639A (zh) 1996-07-18 1999-08-11 美国辉瑞有限公司 基于次膦酸酯的基质金属蛋白酶抑制剂
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
US5817690A (en) * 1996-08-27 1998-10-06 American Home Products Corporation 4-aminoethoxy indolone derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ID22799A (id) 1997-02-03 1999-12-09 Pfizer Prod Inc Turunan-turunan asam arilsulfonilamino hidroksamat
CA2279863A1 (fr) 1997-02-07 1998-08-13 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
EP0960098A1 (fr) 1997-02-11 1999-12-01 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0984930B1 (fr) 1997-05-07 2005-04-06 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
WO1998054093A1 (fr) 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
PL340589A1 (en) 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU4009899A (en) * 1998-05-23 1999-12-13 Tanox, Inc. Molecules targeting cd40 and tumor cells
EP2020408B1 (fr) 1998-05-29 2013-06-26 Sugen, Inc. Dérivé de 2-indolinone substitutée par un pyrrole en tant qu'inhibiteurs de protéine kinase
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
US6114361A (en) 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
CA2342967A1 (fr) 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
AU4685900A (en) * 1999-04-30 2000-11-17 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
JP2003524644A (ja) * 2000-02-01 2003-08-19 タノックス インコーポレイテッド Ｃｄ４０−結合性ａｐｃ−活性化分子
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (fr) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
EP2275446A3 (fr) 2001-01-05 2012-08-15 Pfizer Inc. Anticorps contre le récepteur I de facteur de croissance de type insuline
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
NL1027975C2 (nl) 2004-01-09 2005-12-23 Pfizer Antilichamen tegen MAdCAM.
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
US20090169563A1 (en) 2009-07-02
US7338660B2 (en) 2008-03-04
HUP0402247A3 (en) 2012-09-28
HU229829B1 (en) 2014-09-29
PL370514A1 (en) 2005-05-30
CR7343A (es) 2004-10-28
BRPI0214137B1 (pt) 2019-03-19
CN103450360A (zh) 2013-12-18
CL2009001779A1 (es) 2010-02-05
TW200306204A (en) 2003-11-16
EA011449B1 (ru) 2009-02-27
IL161823A0 (en) 2005-11-20
CR10878A (es) 2011-01-12
US20160152713A1 (en) 2016-06-02
NO334339B1 (no) 2014-02-10
US7618633B2 (en) 2009-11-17
MY137641A (en) 2009-02-27
TWI331040B (en) 2010-10-01
US20060093600A1 (en) 2006-05-04
TW201034686A (en) 2010-10-01
WO2003040170A9 (fr) 2004-06-10
EP1476185A2 (fr) 2004-11-17
JP4616555B2 (ja) 2011-01-19
US8388971B2 (en) 2013-03-05
PA8557701A1 (es) 2003-12-19
UY27537A1 (es) 2003-02-28
US20090130715A1 (en) 2009-05-21
HRP20040525B1 (hr) 2017-06-02
EP2343086A2 (fr) 2011-07-13
ES2432968T3 (es) 2013-12-05
US20120225014A1 (en) 2012-09-06
JP2010213704A (ja) 2010-09-30
JP2013099333A (ja) 2013-05-23
OA12725A (en) 2006-06-28
CN1582165A (zh) 2005-02-16
WO2003040170A2 (fr) 2003-05-15
NI200200128A (es) 2010-01-11
AU2002356926B2 (en) 2007-01-04
EP1476185B1 (fr) 2013-07-31
US20100098694A1 (en) 2010-04-22
PT1476185E (pt) 2013-11-05
US7563442B2 (en) 2009-07-21
GEP20074222B (en) 2007-10-25
JP5547532B2 (ja) 2014-07-16
US7288251B2 (en) 2007-10-30
NO20042388L (no) 2004-08-09
ECSP045093A (es) 2004-07-23
EG25801A (en) 2012-08-08
US20030211100A1 (en) 2003-11-13
US20130024956A1 (en) 2013-01-24
JP5848232B2 (ja) 2016-01-27
NZ533180A (en) 2008-03-28
CA2466128C (fr) 2013-10-29
HUP0402247A2 (hu) 2005-01-28
TWI338579B (en) 2011-03-11
HK1069122A1 (en) 2005-05-13
EP1476185A4 (fr) 2007-04-04
JP2005508176A (ja) 2005-03-31
CN103450360B (zh) 2016-11-02
AR039067A1 (es) 2005-02-09
ZA200404207B (en) 2005-08-31
CN1582165B (zh) 2013-05-29
ME00503B (me) 2011-10-10
PL214289B1 (pl) 2013-07-31
AU2002356926A2 (en) 2003-05-19
US20070190051A1 (en) 2007-08-16
PE20030846A1 (es) 2003-10-11
AP2004003034A0 (en) 2004-06-30
IS7253A (is) 2004-05-06
AP1918A (en) 2008-11-13
KR100830086B1 (ko) 2008-05-20
GT200200228A (es) 2008-09-26
US7626012B2 (en) 2009-12-01
IS2940B (is) 2016-03-15
WO2003040170A3 (fr) 2003-10-09
AU2002356926C1 (en) 2003-05-19
DK1476185T3 (da) 2013-10-14
BR0214137A (pt) 2004-09-14
CA2466128A1 (fr) 2003-05-15
EA200400654A1 (ru) 2004-12-30
KR20050063749A (ko) 2005-06-28
PL392809A1 (pl) 2011-03-14
BRPI0214137B8 (pt) 2021-05-25
CY1115675T1 (el) 2017-01-25
RS52484B (en) 2013-02-28
CU23745A3 (es) 2012-01-31
RS39204A (en) 2006-12-15
HRP20040525A2 (en) 2005-04-30
EP2343086A3 (fr) 2012-02-22
IL161823A (en) 2014-02-27
PL214634B1 (pl) 2013-08-30
DOP2002000507A (es) 2003-05-15
SI1476185T1 (sl) 2013-12-31
MA27139A1 (fr) 2005-01-03
MXPA04004467A (es) 2005-05-16
HN2002000318A (es) 2003-03-10

Similar Documents

Publication Publication Date Title
TNSN04078A1 (fr) Antibodies to cd40
EA012079B3 (ru) Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения
MY140862A (en) ANTIBODIES TO MAdCAM
HK1070907A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
TNSN06080A1 (en) Antibodies to m-csf
MX2007013217A (es) Anticuerpos contra miostatina.
EP2447283A3 (fr) Anticorps monoclonaux humains dirigés contre la kinase-1 du type du récepteur d&#39;activine (ALK-1)
TNSN07398A1 (fr) Anticorps contre la p-cadherine
MA48241A1 (fr) Anticorps dirigés contre madcam
TNSN02089A1 (fr) Anticorps a cd40